ASCO 2016
MPNE at ASCO 2016
Friday, 3 June 2016
Phase 1 trials - changing the Gold standard !
http://www.forbes.com/sites/elaineschattner/2016/06/02/the-emerging-benefit-of-personalized-phase-1-clinical-trials-for-evaluating-targeted-oncology-drugs/#4806e25b7ed3
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment